Filing Details
- Accession Number:
- 0001062993-22-013178
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-05-20 18:13:11
- Reporting Period:
- 2022-05-18
- Accepted Time:
- 2022-05-20 18:13:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1661181 | Organogenesis Holdings Inc. | ORGO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1757373 | S. Gary Gillheeney | C/O Organogenesis Holdings Inc. 85 Dan Road Canton MA 02021 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Acquisiton | 2022-05-18 | 86,531 | $0.99 | 484,773 | No | 4 | M | Direct | |
| Class A Common Stock | Disposition | 2022-05-18 | 86,531 | $5.46 | 398,242 | No | 4 | S | Direct | |
| Class A Common Stock | Acquisiton | 2022-05-19 | 118,504 | $0.99 | 516,746 | No | 4 | M | Direct | |
| Class A Common Stock | Disposition | 2022-05-19 | 118,504 | $5.94 | 398,242 | No | 4 | S | Direct | |
| Class A Common Stock | Acquisiton | 2022-05-20 | 58,654 | $0.99 | 456,896 | No | 4 | M | Direct | |
| Class A Common Stock | Disposition | 2022-05-20 | 58,654 | $5.89 | 398,242 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | Stock Option (Right to Buy) | Disposition | 2022-05-18 | 86,531 | $0.00 | 86,531 | $0.99 |
| Class A Common Stock | Stock Option (Right to Buy) | Disposition | 2022-05-19 | 118,504 | $0.00 | 118,504 | $0.99 |
| Class A Common Stock | Stock Option (Right to Buy) | Disposition | 2022-05-20 | 58,654 | $0.00 | 58,654 | $0.99 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,251,073 | 2024-12-08 | No | 4 | M | Direct | |
| 1,132,569 | 2024-12-08 | No | 4 | M | Direct | |
| 1,073,915 | 2024-12-08 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.39 to $5.62, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.45 to $6.11, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.75 to $6.04, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
- 100% of the shares subject to the option are fully vested and exercisable.
Billionaire Hedge Funds
